Myriad Genetics 8-K
Guidance reaffirmedLeadership change
Vishal Sikri moves from product to commercial leadership, replacing Brian Donnelly; FY2026 guidance reaffirmed.
Filed 2026-09-16 08:00 ET
- 5.02 Officer/director change
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
Commercial leadership change with FY2026 guidance reaffirmed. Vishal Sikri, previously senior vice president of product, became executive vice president of commercial on 9/16/2026. Brian Donnelly ceased serving as chief commercial officer that day and is expected to remain as a non-executive employee through 9/21/2026 to assist with the transition.
Guidance
- FY2026 guidance reaffirmed; figures not restated in this filing.
Investor Takeaways
- FY2026 results will show performance against the reaffirmed full-year guidance.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3